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Abstract
Background: Despite warfarin’s marked efficacy, not all eligible patients receive it for stroke prevention in AF. The
aim of this meta-analysis was to evaluate the association between prescriber and/or patient characteristics and
subsequent prescription of warfarin for stroke prevention in patients with atrial fibrillation (AF).
Methods: Observational studies conducted in the US using multivariate analysis to determine the relationship
between characteristics and the odds of receiving warfarin for stroke prevention were identified in MEDLINE,
EMBASE and a manual review of references. Effect estimates of prescriber and/or patient characteristics from
individual studies were pooled to calculate odds ratios (ORs) with 95% confidence intervals.
Results: Twenty-eight studies reporting results of 33 unique multivariate analyses were identified. Warfarin use
across studies ranged from 9.1%-79.8% (median = 49.1%). There was a moderately-strong correlation between
warfarin use and year of study (r = 0.60, p = 0.002). Upon meta-analysis, characteristics associated with a statistically
significant increase in the odds of warfarin use included history of cerebrovascular accident (OR = 1.59), heart
failure (OR = 1.36), and male gender (OR = 1.12). Those associated with a significant reduction in the odds of
warfarin use included alcohol/drug abuse (OR = 0.62), perceived barriers to compliance (OR = 0.87),
contraindication(s) to warfarin (OR = 0.81), dementia (OR = 0.32), falls (OR = 0.60), gastrointestinal hemorrhage (OR
= 0.47), intracranial hemorrhage (OR = 0.39), hepatic (OR = 0.59), and renal impairment (OR = 0.69). While age per
10-year increase (OR = 0.78) and advancing age as a dichotomized variable (cut-off varied by study) (OR = 0.57)
were associated with significant reductions in warfarin use; qualitative review of results of studies evaluating age as
a categorical variable did not confirm this relationship.
Conclusions: Warfarin use has increased somewhat over time. The decision to prescribe warfarin for stroke
prevention in atrial fibrillation is based upon multiple prescriber and patient characteristics. These findings can be
used by family practice prescribers and other healthcare decision-makers to target interventions or methods to
improve utilization of warfarin when it is indicated for stroke prevention.
Background
Atrial fibrillation (AF) is a common cardiac disorder
with a prevalence ranging from 0.1% in patients < 55
years old to 9.0% in those ≥ 80 years of age. Patients
with AF have a 5-fold increased risk of stroke when
compared to those without AF. Long-term anticoagula-
tion with (adjusted-dose) warfarin is highly efficacious in
preventing stroke in patients with AF [1-3].
While treatment with warfarin increases the risk of
major bleeding, evidence suggests that the benefits of war-
farin outweigh the risks in most patients, including the
elderly [4]. Despite warfarin’s marked efficacy, not all eligi-
ble patients receive it for stroke prevention in AF [5].
Numerous researchers have attempted to elucidate why
warfarin is not consistently used in patients with AF. Pre-
scriber survey studies have found that not all physicians
have a complete understanding of the benefits, risks and
risk-to-benefit ratio of warfarin use for stroke prevention
in AF [6-10]. Furthermore, observational studies have
found that numerous patient characteristics, including
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(but not limited to) advanced age, gender, socioeconomic
status, anticipated or known poor adherence to treatment
or inconsistent follow-up, rural residency, perceived, fall
risk, language difficulties, disabilities and other known or
perceived risk factors for bleeding were independently
associated with the under use of warfarin therapy
[11-38]. Unfortunately, different studies use different
populations, different sample sizes, and different types
and numbers of covariates. Evaluating numerous covari-
ates with a smaller population increases the risk that true
independent predictors will not be found due to lack of
power. As such, not all studies have shown consistent
results making it is difficult to get a picture of true inde-
pendent predictors of warfarin use [5-10].
To more completely identify which prescriber and
patient characteristics are associated with warfarin use,
and to better quantify the magnitude of the effects of
these characteristics, we seek to conduct a systematic
review and meta-analysis of the available medical litera-
ture evaluating the association between such characteris-
tics and U.S. prescriber use of warfarin for stroke
prevention in AF. Having such an analysis available will
allow family practice prescribers and other healthcare
decision-makers to target interventions or methods to
improve utilization of warfarin when it is indicated for
stroke prevention in AF.
Methods
Literature Search and Data Abstraction
Two independent investigators conducted systematic lit-
erature searches of the MEDLINE and EMBASE (earliest
possible date through October 2010) computerized data-
bases. The MeSH terms and keywords: warfarin, couma-
din, coumarins, vitamin k antagonist, coumatetralyl,
phenprocoumon, dicoumarol, tioclomarol, phenindione,
clorindione, fluindione, diphenadione and indandione,
along with atrial fibrillation were used. The utilized
search strategy is included in See additional file 1: Search
Strategy. Additionally, the American College of Chest
Physicians (ACCP) guidelines [39,40] were reviewed
along with the references of each pertinent article identi-
fied to locate other relevant published works.
Studies were eligible for inclusion in the systematic
review if they: (1) reported on a population of patients
with atrial fibrillation, (2) reported on the relationship
between prescriber and/or patient characteristics and the
odds of receiving warfarin for stroke prevention, (3) con-
ducted multivariate analysis to determine the relationship
between prescriber and/or patient characteristics and the
odds of receiving warfarin therapy, (4) enrolled patients
treated in the United States only, (5) were published in
English language, and (6) was published no earlier than
1996. The year for this later criterion was based upon the
year of publication of the seminal study of warfarin risks
and benefits by Hylek and colleagues published in the
New England Journal of Medicine [41].
Through the use of a standardized data abstraction
tool, two reviewers independently determined whether or
not an article was to be included in the systematic review
and collected data, with disagreement resolved through
discussion. For each included study, data on the following
was abstracted: author, year, study design, sample size,
population and setting, exclusion criteria, whether studies
were restricted to “ideal candidates” for warfarin or not
(defined patient populations without warfarin contraindi-
cations), timing and duration of study period, (percent of
patients receiving warfarin, manner of determining war-
farin use, p-value for the univariate relationship between
a prescriber or patient characteristic and warfarin use,
and effect size and p-value for the multivariate relation-
ship between a prescriber or patient characteristic and
warfarin use.
Validity Assessment
Validity assessment was performed using the methodol-
ogy utilized by the Agency for Healthcare Research and
Quality (AHRQ) Evidence-based Practice Center pro-
gram [42]. For the purposes of validity assessment in this
systematic review, an evaluation was defined as an assess-
ment of a prescriber or patient characteristic for its asso-
ciation with warfarin use (thus a single study likely
included evaluations of multiple different characteristics).
Each evaluation included in a study was separately
assessed for the following individual criteria: hierarchy of
study design, total, characteristic and warfarin use sample
sizes, participant selection method, exposure measure-
ment method (warfarin use), potential design biases, and
appropriate analyses to control for confounding. Each
evaluation in all identified studies were then be given an
overall score of good, fair or poor as described in addi-
tional file 2: Three Summary Ratings of Quality of Indivi-
dual Studies.
Data Synthesis
Results of our systematic literature search were first sum-
marized qualitatively using descriptive statistics. Qualita-
tive synthesis consisted of detailed evidence tables and
figures (stratified by CHADS2 criteria [43], characteristics
listed in the black box warning of Coumadin’s® prescrib-
ing information, contraindications or strong precautions
listed in the prescribing information, and “other” charac-
teristics [44]) demonstrating the number, overall conclu-
sions, and assessed validity of evaluations stemming form
multivariate analyses. We also assessed the change in
warfarin use over time (defined as earliest year of patient
inclusion) through utilization of linear regression analysis
and report the Pearson’s r value and its corresponding
p-value.
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We also undertook traditional meta-analysis for each
prescriber and patient characteristic with at least 2 studies
reporting data. We calculated weighted averages of effect
size as pooled (adjusted) odds ratios (ORs) with associated
95% confidence intervals (CIs) using a DerSimonian and
Laird random-.effects model. When studies reported
results from overlapping populations (either in same of
separate publications), we preferentially used the most
recent data for meta-analysis, followed by the largest sized
population if study period could not be used. The likeli-
hood of statistical heterogeneity was assessed for in each
analysis using the I2 statistic and Cochrane Q statistic p-
values (either an I2 > 50% and a Cochrane Q statistic p <
0.10 were considered representative of important statistical
heterogeneity). Egger’s weighted regression statistic
p-values were used to assess for the likelihood of publica-
tion bias. Traditional meta-analysis statistics were per-
formed using StatsDirect statistical software, version 2.7.6
(StatsDirect Ltd, Cheshire, UK). A p-value less than 0.05
will be considered statistically significant for all analyses.
Grading the Strength of Evidence
We used the Grading of Recommendations Assessment,
Development (GRADE) system to assess the strength of
evidence [45]. This system uses four required domains -
risk of bias, consistency, directness, and precision.
Strength of evidence grade was determined for each asso-
ciation between prescriber and patient characteristics and
warfarin use for stroke prevention in AF. The evidence
pertaining to each prescriber and patient characteristic
was classified into four broad categories: (1) “high”, (2)
“moderate”, (3) “low” grade or “insufficient” as described
in additional file 3: Definitions for Grading the Strength
of Evidence.
Results
Study Identification and Characteristics
A summary of the results for our literature search are
presented in additional file 4: Study Flow Diagram. A
total of 1,060 non-duplicate citations were identified, of
which 208 citations were retrieved for full-text review. Of
these, 28 articles published between 1996 and 2010,
representing 33 unique analyses met our inclusion cri-
teria [11-38]. (Table 1). Of note, the studies by Stafford
1996, Brass 1998, Smith 1999 and Brophy 2004 each
reported the results of 2 multivariate analyses on overlap-
ping populations [16,18,33,35]. Moreover, the studies by
Schauer 2007 and Johnston 2003 were conducted in the
same database and with overlapping, but not similar time
frames [23,32]. The studies by Antani 1996 and Beyth
1996 were conducted in the same population (although
the analysis in the Beyth paper has slightly fewer patients
due to incomplete data collection) [13,14]. Finally, Lewis
2009 also conducted 2 multivariate analyses; however,
the populations used were mutually exclusive and thus
these analyses were treated as unique data points in our
report [24]. Of the 28 studies identified, 4 were con-
ducted in a prospective and 24 in a retrospective fashion.
Sample sizes of studies ranged from 117 to 44,193
patients. While studies were published between 1996 and
2010, they evaluated patients treated for atrial fibrillation
between 1980 and 2008. Five studies (17.9%) reported
results of analyses restricted only to patient populations
without warfarin contraindications (’ideal candidates’)
[18,24,25,29,30].
Results of Qualitative Synthesis
Warfarin use across included studies ranged from 9.1%
to 79.8%, with a median of 49.1%. Linear regression
analysis on the 23 studies providing data on warfarin
use suggests that there is a statistically significant,
moderately strong (per Cohen’s Rule of Thumb) [46]
correlation (r = 0.60) between warfarin utilization and
progressing time. (Figure 1) This finding was not sig-
nificantly changed when studies enrolling ‘ideal candi-
dates’ only were excluded (data not shown).
See additional file 5, 6, 7 and 8: Figures Depicting the
Number, Validity and Statistical Conclusions of Studies
Evaluating Associations Between Characteristics and War-
farin Use and additional file 9: Tables Depicting the Asso-
ciation Between Covariates and Warfarin Use for Stroke
Prevention in Atrial Fibrillation) for figures and tables
depicting the number, validity and statistical conclusions
of identified studies evaluating associations between pre-
scriber and patient characteristics and warfarin use. Char-
acteristics had anywhere from 1 (multiple characteristics)
to 16 (age) evaluation data points. Age, congestive heart
failure, cerebrovascular accident, hypertension, male gen-
der, renal impairment, prescriber specialty, geographic
region and race were the most commonly evaluated in
identified studies (all evaluated ≥ 5 times). Thirty-seven
prescriber or patient characteristics were reported only
once in included studies. (Table 2). Furthermore, 17 addi-
tional characteristics (malignancy, categorical age, admis-
sion source, prescriber specialty, insurance status, region
of country treated in, race, rate of prior healthcare utiliza-
tion, year of evaluation, and type of AF, aspirin or other
antiplatelet use, perceived appropriateness of warfarin,
perceived/actual risk of bleeding, seizures, increasing risk
of stroke/embolic event) were identified in studies which
were deemed inappropriate for pooling because of hetero-
geneity in characteristic definition or inconsistencies in
data reporting.
For the most part, evaluations of characteristics were rated
as being of “good” or “fair” quality, with only 69 of 229
(69.9%) evaluations rated as “poor”. Most characteristics
were found to have conflicting data in regards to their
effect on warfarin use. Only 6 characteristics with more
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44,193 R, O Patients aged ≥ 40 years who were hospitalized
and had a diagnosis of AF (ICD-9: 427.xx).
Patients with hyperthyroidism or who were
pregnant.







258 P, O Patients aged ≥ 45 years from the Reasons for
Geographic and Racial Difference in Stroke
(REGARDS) study who have positive EKG
evidence of AF and self-report AF during in-
home visit
None Current aspirin and warfarin treatment was
defined using
an inventory of current medications that was
conducted as part of the in-home visit, in which
all prescription and over-the-counter










Consecutive patients in the Get with the
Guidelines program Stroke database presenting
with ischemic stroke or TIA (ICD-9: 433 to 436)
and AF documented using EKG during the
admission
Patients with documented contraindication to
anticoagulation; patient death, leaving against
medical advice, discharged to hospice, or
transferred to another acute-care facility









Consecutive patients in the Get with the
Guidelines program Stroke database presenting
with ischemic stroke or TIA (ICD-9: 433 to 436)
and AF documented using medical history only
Patients with documented contraindication to
anticoagulation; patient death, leaving against
medical advice, discharged to hospice, or
transferred to another acute-care facility




Niska, 2009 1,771 R, O Random, representative, and multistage sample
from the National Ambulatory Medical Care
Survey (NAMCS) and the National Hospital
Ambulatory medical Care Survey (NHAMCS) of
patient visits; patients were aged ≥ 20 years,
had a diagnosis of AF (ICD-9-CM: 427.31)
Malignant or benign brain neoplasms, bleeding
disorders, alcoholism, Alzheimers and other
dementias, seizure disorders, chronic renal
disease, cerebal hemorrhage, liver disease, peptic
ulcer disease, gastritis, or duodenitis









Patients hospitalized with HF and either AF
upon admission or a prior history of AF in the
Get With The Guidelines-Heart Failure (GWTG-
HF) registry
Documented contraindications, intolerance, or
other documented reasons for not prescribing
warfarin; medical histories with < 75%
completeness or conflicting data fields
Warfarin use at discharge (65.2%) 2005-
2008
Glazer, 2007 572 R, O Patient aged between 30 to 84 years with newly
detected AF (first clinically recognized lifetime
episode of non-surgery-related AF, ICD-9:427.31,
(atrial flutter) 427.32) in a health maintenance
organization (Group Health Cooperative)
database
Patients who died during hospitalization, had a
pacemaker implanted before AF onset, or had
fewer than 4 health care visits any time before
AF onset date.
Warfarin use during 6-month follow up period









6,283 R, O White and African-American Ohio Medicaid
patients with newly incident nonvalvular AF
(ICD-9-CM: 427.31); patients must have at least 2
claims for AF and have a full year of continuous
Ohio Medicaid enrollment without diagnosis of
AF before the first diagnosis
Patients who filled any warfarin prescriptions
more than 7 days prior to the diagnosis of AF;
patients with a history of valvular heart disease
prior to the diagnosis of AF, as ascertained by 2
or more claims for mitral valve disease, heart
valve transplant, heart valve replacement, or a
procedure code for mitral or aortic valve repair
or replacement; patients for whom race could
not be determined
Claim for a warfarin prescription at any time
between 7 days prior to the initial diagnosis of


























17,272 R, O Patients (from the National Registry of Atrial
Fibrillation II) with medicare Part A and Part B
claims who were hospitalized with AF
Patient who died during baseline hospitalization,
had a terminal illness, had no Medicare Part B
claims during follow-up, or were aged < 65
years at baseline
Patients discharged with warfarin prescription




Hylek, 2006 405 P, O Consecutive patients identified by daily searches
of electronic admission notes and EKGs of all
admissions to Massachusetts General Hospital
that had AF verified by EKG, were aged ≥ 65
years, not taking warfarin on admission, and had
longitudinal care provided at the institution
Other long-term indication for warfarin therapy Started on and discharged with warfarin







178 R, O Patients with a AF diagnosis (ICD-9-CM:427.31)
in a database shared by two ambulatory care
clinics
Patients with a primary care physician at another
facility






117 R, O LTC patients with chronic or paroxysmal AF
either by diagnosis or EKG
NR Warfarin use for 6 months or longer according
to pharmacy or medical records
(46.1%)
NR
Lim, 2005 2,011 R, O A random sample of Medicare fee-for-service
patients discharged from Michigan’s acute care
hospitals (excluding Veteran’s Administration)
with a primary or secondary discharged
diagnosis of AF (ICD9-CM:427.31); patients who
met national guidelines for anticoagulant
therapy
Patients with lone AF, aged < 65 years, planned
surgery within 7 days of discharge or recent
surgery, physician documentation of risk for falls,
alcoholism or drug abuse (history or current),
dual chamber pacemaker (history or current),
schizophrenia/active psychosis (history or
current), extensive metastatic cancer (history or
current), brain or central nervous system cancer
(history or current), seizures (history or current),
malignant hypertension (history or current), CVA
hemorrhagic (history or current), peptic ulcer
(current), intracranial surgery/biopsy (current),
hemorrhage (history or current), and physician
documentation of rationale for not prescribing
warfarin




Waldo, 2005 945 R, O Randomly chosen patients from select hospitals
participating in the National Anticoagulation
Benchmark and Outcomes Report (NABOR)
program who were discharged with a primary
or secondary diagnosis of AF (ICD-9-CM: 427.31)
Patients aged < 18 years, admitted from another
acute care hospital where warfarin therapy was
already initiated, or discharged to another acute







2,217 R, O Patients with a documented healthcare
encounter in the Veterans Affairs Boston
Healthcare System database, electrocardiogram-
documented AF in the Marquette Universal
Storage for Electrocardiograms database, and a
verified diagnosis code for AF [ICD-9-CM: 427
(.3,.31)] in the national Veterans Affairs database
Patients with valvular heart disease [ICD-9-CM:
391.1, 394(.0-.2), 396(.0-.3,.8), 424.0, 746(.5,.6)]
A prescription for warfarin in the Veterans Affairs



























1,596 R, O Patients with a documented healthcare
encounter in the Veterans Affairs Boston
Healthcare System database, electrocardiogram-
documented AF in the Marquette Universal
Storage for Electrocardiograms database, and a
verified diagnosis code for AF [ICD-9-CM: 427
(.3,.31)] in the national Veterans Affairs database
Patients with a contraindication to warfarin use,
or valvular heart disease [ICD-9-CM: 391.1, 394(.0-
.2), 396(.0-.3,.8), 424.0, 746(.5,.6)]
Any prescription for warfarin in the Veterans






R, O Patients with AF (ICD-9-CM: 429.31) from the
National Ambulatory Medical Care Survey
(NAMCS), a nationally representative assessment
of office-based practice
Providers not in internal medicine, general
practice, family practice, cardiology, or cardiac
electrophysiology; patients with the following
diagnosis: dementia, gait abnormalities, epilepsy,
intracranial hemorrhages, gastritis or duodenitis,
gastrointestinal ulcer disease, gastrointestinal
hemorrhages, chronic liver disease, alcoholism,
purpura, hematuria, and neoplasms of the







Rahimi, 2004 290 R, O Patients with a diagnosis of AF requiring
anticoagulation therapy admitted to a
community-based teaching hospital in
Southeast Georgia
Patients with hypercoagulable state,
hemorrhagic stroke, carotid stenosis, peripheral







11,699 R, O Patients in the Ohio Medicaid Program database
with a first diagnosis of AF
Patients enrolled in capitated plans in the Ohio
Medicaid Program and those who did not have
a full year of continuous Ohio Medicaid
enrollment without diagnosis of AF before the
first diagnosis; patients with other indications for
warfarin including valvular heart disease and
valve repair or replacement; patients with
transient AF including ones with a single ICD-9-
CM code for AF associated with a ICD-9-CM
code for hyperthyroidism or a ICD-9-CM code
for operative procedures commonly associated
with perioperative or postoperative AF’ patients
already receiving warfarin prior to AF diagnosis
Claim in Ohio Medicaid administrative database
for warfarin use (ICD-9-CM:V58.61) or warfarin
prescription from 7 days preceding to 30 days






429 R, O LTC patients in Connecticut with diagnosis of
AF confirmed by EKG or written documentation
by the LTC facility’s physician
Patients who had resided in the LTC facility for
< 30 days or had end-stage renal disease
Receipt of warfarin therapy for ≥ 2 weeks
during the prior 12 months
(42%)
NR
Go, 1999 13,428 R, O Patient in a health maintenance organization
(Kaiser Permanente Medical Care Program in
Northern California) database who had a
diagnosis of nonvalvular AF (ICD-9-CM: 427.31)
recorded in the automated outpatient database
and an electrocardiogram showing AF in the
electrocardiographic database (if database was
available at time of diagnosis)
Patients with the following characteristics: no
health membership after diagnosis of AF, age
younger than 18 years, transient AF secondary
to cardiac surgery, mitral stenosis or mitral or
aortic valve repair or replacement, concomitant
hyperthyroidism, or no outpatient, internal
medicine, or cardiology care during 12 months
after first diagnosis of AF
Having either a filled prescription for warfarin or
dicumarol in the pharmacy database, more than
one outpatient INR, or a diagnosis of
“Coumadin therapy” (ICD-9: V58.61) 3 months























Table 1 Characteristics of Included Studies Evaluating the Association Between Covariates and Warfarin Use for Stroke Prevention in Atrial Fibrillation
(Continued)
Smith, 1999a 144 P, O Patients from the Cardiovascular Health Study
(CHS) aged ≥ 65 years with EKG-identified
prevalent AF (paroxysmal or chronic)
Patients with a mechanical pacing device; AF
patients too ill to participate further or not
available for follow-up






Smith, 1999b 135 P, O Patients from the Cardiovascular Health Study
(CHS) aged ≥ 65 years with EKG-identified
prevalent AF (paroxysmal or chronic)
Patients with a mechanical pacing device; AF
patients too ill to participate further or not
available for follow-up








White, 1999 172 P, O Subgroup of patients aged ≥ 70 years in the
Cardiovascular Health Study with AF on EKG at
one or more yearly examinations along with
information regarding warfarin use and no pre-
existing indication for its use
Patients who were in nursing homes, wheel-
chair bound, had a mechanical heart valve, had
a history of DVT or PE before starting warfarin
therapy, being treated for cancer, or taking
warfarin prior to onset of AF




Brass, 1998a 278 R, O Medicare patients aged ≥ 65 years hospitalized
with a a principal diagnosis of of ischemic
stroke using ICD-9 codes and discharged alive
with a primary or secondary diagnosis of AF
Patients with a potential indication for
anticoagulation other than AF including patients
with primary diagnosis of AMI or embolic events
(other than stroke); patients with retinal vascular
occlusion, peripheral vascular disease, vascular
insufficiency of the intestine, and vascular
disorders of the kidney
Prescribed warfarin at discharge (53%) 1994
Brass, 1998b 203 R, O Medicare patients aged ≥ 65 years hospitalized
with a a principal diagnosis of of ischemic
stroke using ICD-9 codes, discharged alive with
a primary or secondary diagnosis of AF and not
receiving warfarin at time of admission
Patients with a potential indication for
anticoagulation other than AF including patients
with primary diagnosis of AMI or embolic events
(other than stroke); patients with retinal vascular
occlusion, peripheral vascular disease, vascular
insufficiency of the intestine, and vascular
disorders of the kidney





R, O Nationally representative and random sample of
office visits by patients with AF (ICD-9-CM:
427.31) from the National Ambulatory Medical
Care Surveys
Patients with potential contraindications for
anticoagulation, including peptic ulcer disease,
gastritis and duodenitis, other gastrointestinal
bleeding, alcoholism, gait abnormality, ataxia,
Alzheimer’s or other dementia, cerebral
hemorrhage, seizure disorder, benign or
malignant central nervous system tumors,
gastrointestinal and genitourinary tract renal
malignancies, thrombocytopenia, hematuria,
esophageal varices, and renal insufficiency;
patients < 65 years old lacking other risk factors
for stroke (CHF, ischemic heart disease, diabetes
mellitus, hypertension, valvular disease, or
previous stroke); patient visits made to
physicians other than cardiologists, general
internists, family physicians, and general
practitioners























Table 1 Characteristics of Included Studies Evaluating the Association Between Covariates and Warfarin Use for Stroke Prevention in Atrial Fibrillation
(Continued)
Brass, 1997 488 R, O Medicare patients aged ≥ 65 years with
established AF (before hospitalization) who were
hospitalized with a principal diagnosis (reason
for admission) of ischemic stroke and a
secondary diagnosis of AF (ICD-9:427.31);
patients without stroke were selected with a
primary or secondary discharge diagnosis of A
and matched to one patient with stroke on age
(within 1 year), sex, and secondary diagnoses of
hypertension, non-insulin-dependent diabetes,
insulin-dependent diabetes, congestive heart
failure, angina, and myocardial infarction as a
nonprimary diagnosis
Patients with a potential indication for
anticoagulation other than AF including patients
with primary diagnosis of AMI or embolic events
(other than stroke); patients with retinal vascular
occlusion, peripheral vascular disease, vascular
insufficiency of the intestine, and vascular
disorders of the kidney






651 R, O Patients discharged from hospital with AF (ICD-
9: 427.31)
Patients with transient or paroxysmal AF, a
recent major surgical procedure, or undergoing
treatment for active malignancy






189 R, O Consecutive inpatients with nonrheumatic AF
discharged alive with a discharged diagnosis of
AF (ICD-9: 427.31) and confirmed by review of
medical records, or outpatients with
nonrheumatic AF
Patients with transient AF, history of rheumatic
fever or rheumatic heart disease, or lone AF








136 R, O Consecutive patients with sustained or
intermittent nonrheumatic AF







R, O Visits by patients with AF (ICD-9-CM:427.31) to
randomly selected office-based physicians
included in the National Ambulatory Medical
Care Surveys
Visits by patients with atrial flutter (ICD-9-
CM:427.32)
A medication code for warfarin (generic or








R, O Visits by patients with AF (ICD-9-CM:427.31) to
randomly selected office-based physicians
included in the National Ambulatory Medical
Care Surveys
Visits by patients with atrial flutter (ICD-9-
CM:427.32)
A medication code for warfarin (generic or




Abbreviations: AF: atrial fibrillation, AMI: acute myocardial infarction, CM: clinical modification, CS: cross-sectional, EKG: electrocardiogram, CVA: cerebral vascular accident, DVT: deep-vein thrombosis, HF: heart failure,




















than one data point were found to be consistently asso-
ciated with [aspirin or other antiplatelet use (n = 4 evalua-
tions), perceived appropriateness of warfarin (n = 2
evaluations), progressing time (n = 2 evaluations), demen-
tia (n = 3 evaluations), AF frequency (n = 3 evaluations)
and progressing time (n = 2 evaluations)] or without [cor-
onary artery disease (n = 4 evaluations), seizures (n = 2)] a
statistically significant effect on warfarin utilization. No
characteristic was found to be significantly associated with
both an increase and decease in warfarin use.
Results of Meta-Analysis
Meta-analysis was possible for 18 different prescriber and
patient characteristics. The results of these analyses are
summarized in Table 3. Upon meta-analysis, characteris-
tics associated with a statistically significant increase in the
odds of warfarin use included history of cerebrovascular
accident (OR = 1.59), congestive heart failure (OR = 1.36),
and male gender (OR = 1.12). Those associated with a sta-
tistically significant reduction in the odds of warfarin use
included alcohol or drug abuse (OR = 0.62), perceived bar-
riers to compliance (OR = 0.87), contraindication(s) to
warfarin (OR = 0.81), dementia (OR = 0.32), falls (OR =
0.60), gastrointestinal hemorrhage (OR = 0.47), intracra-
nial hemorrhage (OR = 0.39), hepatic impairment (OR =
0.59), and renal impairment (OR = 0.69). Age per 10-year
increase (OR = 0.78) and advancing age as a dichotomized
variable (OR = 0.57) were associated with a statistically
significant reduction in warfarin use. Diabetes (OR = 1.11,
p = 0.13), history of bleeding (OR = 0.47, p = 0.06) and
hypertension (OR = 1.34, p = 0.06) all showed trends
towards effect, but failed to reach the a priori cut-off for
statistical significance. Coronary artery disease did not
























Figure 1 Result of a Linear Regression Analysis Evaluating the
Correlation Between Warfarin Use Over Progressing Time.
Dotted lines represent timing of seminal warfarin publications
(Hylek 1996 and 2001 Update of the AHA/ACC Atrial Fibrillation
Guidelines) [42,44]. As studies were plotted on the horizontal axis
based upon the first year of patient inclusion, data on warfarin use
prior to 1996 is depicted. r = Pearson’s correlation coefficient.
Table 2 Association Between Prescriber and Patient Characteristics with Only One Data Point and Warfarin Use
Not Associated with Warfarin Use Associated with Increased Warfarin Use Associated with Decreased Warfarin Use
Married Vascular malformation Fractures
Education Hyperlipidemia Albumin ≤ 30 g/L
Vascular aneurysm or arteriovenous
malformation
Body mass index per 5 kg/m2 increase Anemia
Prosthetic valve Heart rate per 10 beats per minute increase Chronic obstructive pulmonary disease or
asthma
Mitral stenosis Male subject without prior cerebral vascular accident Limited activities of daily living before
admission
Valvular disease Beta-blocker use
Rheumatic heart disease Angiotensin-converting enzyme inhibitor use
Larger left atrial dimension Diuretic use
History of atrial thrombus Warfarin use upon admission
Terminal illness Access to clinic with anticoagulation management
services
Recent major surgery Number of hospital beds, per 100 bed increase
Male subject with prior cerebral vascular
accident
Location of diagnosis (hospital)
Digoxin use Another indication for warfarin use
Nonsteroidal antiinflammatory use
Coagulopathy or thrombocytopenia
Access to medical care
Inpatient status
Treatment at a community hospital
Physicians’ experience with warfarin
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Statistical heterogeneity (I2 > 50% or a Cochrane Q p
< 0.10) was found to be present in over half of the char-
acteristics evaluated. However in most cases, the hetero-
geneity appeared to be due to variance in the magnitude
and not the direction of effect.
Review of Egger’s weighted regression statistic p-values
suggested a lower likelihood of publication bias (p > 0.17
for all evaluable); however, many (n = 10) analyses con-
tained too few studies to allow for proper assessment.
Twenty-one (75%) of included studies reported at least
one nonsignificant result suggesting a lower likelihood of a
negative reporting bias (failure to report nonsignificant
results).
Strength of Evidence Grading
Results of strength of evidence grading are found in
Table 4. Four prescriber or patient characteristic associa-
tions with warfarin use were found to have a “high”, 20 a
“moderate”, and 3 a “low” strength of evidence rating.
Five characteristics with more then one evaluation
reported in identified studies were deemed to have data
‘insufficient” to make rate the strength of evidence. Based
upon the limited amount of data, the strength of evidence
for all prescriber and patient characteristics evaluated
only once in identified studies (n = 370) was automati-
cally deemed “insufficient” and have not included in the
strength of evidence table.
Discussion
It has been suggested that the complex nature of warfarin
prescribing has resulted in under prescribing of warfarin
for stroke prevention in AF patients [5]. Our systematic
review and meta-analysis confirm this assertion of under
prescribing of real-word warfarin (median ~ 49%); how-
ever, it also suggested that warfarin utilization has been
increasing somewhat over time. This increase in prescrib-
ing may be a result of greater awareness of the benefit-to-
risk ratio of warfarin in this setting stemming from
updated treatment guidelines and national organization
campaigns such as the American Cancer Society, Ameri-
can Diabetes Association and American Heart Associa-
tion’s “The Guideline Advantage” initiatives [47]. In
addition, our analysis suggests that a prescriber’s decision
to administer warfarin for stroke prevention based upon
the interaction of multiple prescriber and patient charac-
teristics. Upon meta-analysis, independent positive predic-
tors of warfarin use included history of cerebrovascular
accident, congestive heart failure, and male gender. Inde-
pendent negative predictors included alcohol or drug
abuse, perceived barriers to compliance, contraindication
(s) to warfarin, dementia, falls, gastrointestinal hemor-
rhage, intracranial hemorrhage, hepatic impairment, and
renal impairment. Upon qualitative analysis of characteris-
tics with data not suitable for pooling, 5 additional positive
predictors and 4 additional negative predictors of warfarin
Table 3 Results of Meta-Analysis Evaluating the Association Between Prescriber and Patient Characteristics and
Warfarin Use
Characteristic N Studies Pooled OR (95%CI) I2 Qp Egger’s p
Advancing (dichotomous) age* 11 0.57 (0.39-0.82) 79% < 0.0001 0.40
Age per 10 year increase 4 0.78 (0.68-0.90) 70% 0.02 0.20
Alcohol or drug abuse 2 0.62 (0.40-0.96) NA 0.72 NA
Coronary artery disease 3 1.08 (0.82-1.42) 39% 0.20 NA
Congestive heart failure 8 1.36 (1.18-1.57) 84% < 0.0001 0.60
Contraindications to warfarin 3 0.81 (0.69-0.96) 0% 0.58 NA
Cerebral vascular accident 10 1.58 (1.15-2.18) 93% < 0.0001 0.84
Dementia 3 0.32 (0.14-0.75) 78% 0.01 NA
Diabetes 2 1.11 (0.97-1.26) NA 0.52 NA
Falls 4 0.60 (0.43-0.85) 83% 0.0006 0.25
Gastrointestinal bleeding 3 0.47 (0.40-0.55) 0% 0.51 NA
History of bleeding 3 0.47 (0.21-1.03) 80% 0.007 NA
Hepatic impairment 2 0.59 (0.50-0.70) NA > 0.99 NA
Hypertension 5 1.34 (0.99-1.81) 91% < 0.0001 0.48
Intracranial bleeding 3 0.39 (0.28-0.55) 2% 0.36 NA
Male gender 11 1.12 (1.04-1.21) 58% 0.008 0.17
Perceived barriers to compliance 2 0.87 (0.76-0.99) NA 0.32 NA
Renal impairment 6 0.69 (0.60-0.80) 70% 0.005 0.40
N = number of studies; NA = not available/applicable; OR = odds ratio; Qp = Q statistic p-value
*Advancing age analysis included any study reporting the odds of warfarin use dichotomously stratified by age. Age of stratification may have been 65, 75, or 80
years of age and was not disclosed in one study
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use were identified. The strength of evidence supporting
these conclusions was for the most part deemed “high” to
“moderate”. Interestingly, many of the characteristics iden-
tified as negative independent predictors of warfarin use
are integral parts of commonly used anticoagulation and
bleeding risk prediction schemas [48].
Age was the most evaluated patient characteristic in
identified studies. Interestingly, both the age per 10 year
increase and dichotomous advancing age covariates
demonstrated statistically significant reductions in war-
farin use with increasing or advanced age. However, quali-
tative review of results of studies which evaluated age as a
categorical variable reveals that the youngest of AF
patients do not receive warfarin as commonly, likely as a
result of perceived lack of stroke risk [2,43]. As patients
age, they begin to be prescribed warfarin more; however,
this increased utilization continues only until patients
reach a more advanced age (~ 75-80 years old) at which
Table 4 Strength of Evidence Supporting the Systematic review and Meta-Analysis’ Conclusions
Characteristic Conclusion Strength of Evidence Rating
Meta-Analyzable Characteristics
Alcohol and drug use Reduces warfarin use High
Increasing age Decreased warfarin use at older ages Moderate
Coronary artery disease No effect in warfarin use Moderate
Congestive heart failure Increases warfarin use Moderate
Contraindications to warfarin Reduces warfarin use High
Cerebral vascular accident Increases warfarin use Moderate
Dementia Reduces warfarin use Moderate
Diabetes No effect on warfarin use Low
Falls Reduces warfarin use Moderate
Gastrointestinal bleeding Reduces warfarin use High
History of bleeding Reduces warfarin use Moderate
Hepatic impairment Reduces warfarin use Moderate
Hypertension No effect on warfarin use Low
Intracranial bleeding Reduces warfarin use High
Male gender Increases warfarin use Moderate
Perceived barriers to compliance Reduces warfarin use Moderate
Renal impairment Reduces warfarin use Moderate
Qualitatively Assessed Characteristics
Race (African-American or non-White) Reduces warfarin use Moderate
Geographic region (South) Reduces warfarin use Moderate
Geographic region (Northeast) Increases warfarin use Moderate
Malignancy Equivocal Insufficient
Progressing time Increases warfarin use Moderate
Specialty of prescriber Equivocal Insufficient
Insurance status Equivocal Insufficient
Aspirin or other antiplatelet use Reduces warfarin use Moderate
Perceived appropriateness of warfarin
(appropriate)
Increases warfarin use Moderate
Perceived/actual risk of bleeding Reduces warfarin use Moderate
Admission source (home/outpatient) for
AF hospitalization
Increases warfarin use Moderate
AF frequency (recurrent, persistent,
permanent)
Increases warfarin use Moderate
Seizures No effect on warfarin use Low
Increasing risk of stroke/embolic event Equivocal Insufficient
Rate of prior healthcare utilization Equivocal Insufficient
AF = atrial fibrillation
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point warfarin use is reduced once again. These results
suggest the relationship between age and warfarin use is
complex and nonlinear in nature based heavily upon bal-
ancing of stroke and bleeding risks. Consequently, includ-
ing age into a multivariate model as a continuous or even
dichotomous variable will likely provide a result that is in
error. Future studies should be careful to avoid oversimpli-
fying the association between age and warfarin use.
Surprisingly, hypertension and diabetes both characteris-
tics comprising the CHADS2 score) were not found to be
independent positive predictors of warfarin prescribing,
although trends were observed in our analysis (p = 0.06
and 0.13, respectively). The lack of statistically significant
findings, even after pooling, is possibly a result of type 2
error. For example, hypertension was assessed by only 5
studies in this meta-analysis. Hypertension is also com-
mon in AF patients, with ~75% patients enrolled in recent
randomized trials reporting it as a comorbid condition
[49,50]. The infrequent reporting and small number of
patients without the characteristic in a given study, make
it particularly difficult to demonstrate significant effects.
Of note, both gender and race appeared to be asso-
ciated with warfarin prescribing even after adjustment for
confounding through multivariate analysis. Our analysis
found that men had a 12% increased (pooled) odds of
receiving warfarin for stroke prevention compared to
women, and that African-American patients were any-
where from 24% to 69% less likely to receive warfarin.
These data may suggest the presence of gender and racial
inequalities in AF care in the US. Furthermore, warfarin
appeared to be prescribed to patients more commonly in
the Northeast and less commonly in the South. These
later findings are consistent with prior data suggesting
the provision of healthcare in the Northeast is often
more in line with select quality metrics and clinical prac-
tice guidelines [51].
It should be noted that our systematic review and meta-
analysis only attempted to identify predictors of warfarin
initiation or use during a defined period of time and not
predictors of warfarin persistence. In a recent study by
Fang and colleagues, over 25% of patients newly started on
warfarin for AF were found to discontinue therapy in the
first year [52]. Patients of a younger age and those with
fewer stroke risk factors and poorer international normal-
ized ratio (INR) control were found to be less likely to
remain on warfarin.
Interestingly, not all available research suggests that
warfarin is underused for stroke prevention in AF [53].
While not included in our systematic review because it
failed to meet inclusion criteria, Weisbord and colleagues
[53] surveyed primary care providers and concluded that
few patients with AF and no contraindications to oral
anticoagulation were not receiving warfarin. Most
importantly, the results of this study compel us to con-
sider a number of prescriber and/or patient characteris-
tics that might not have been captured by studies
included in our systematic review, such as previous
adverse events on warfarin, polypharmacy, remote living
and patient unwillingness to take warfarin.
There are a number of limitations of our systematic
review and meta-analysis that should be noted. First,
observational studies - such as those included in our
review - are prone to bias. Perhaps most concerning in
this case, is the potential of misclassification bias, or the
improper coding of an AF diagnosis, warfarin prescrip-
tion, or one the prescriber and/or patient characteristics.
All included studies utilized databases detailing patient
diagnoses and warfarin utilization; however, many of
these databases were likely never designed for research
purposes. Moreover, these databases typically included
only a fraction of prescriber and/or patient characteristics
that could potentially be a predictor of warfarin prescrib-
ing. Thus, some prescriber and/or patient characteristics
were identified as independent predictors more often
than others, not necessarily because of a true or more
potent relationship, but because it was more commonly
collected in analyzed databases. Also of import, individual
studies were often conducted in local or regional data-
bases, so their results may not reflect a US AF population
as a whole. Next, there was unexplained statistical hetero-
geneity present in many of our meta-analyses of prescri-
ber and patient characteristics. Importantly, however,
disagreement between studies seemed to be a result in
differences in estimation of the magnitude and not direc-
tion of effect. While we were unable to determine defini-
tive causes for this heterogeneity, it is likely a result of
differences in patient populations evaluated (inclusion
and exclusion criteria, ideal vs. not ideal populations) in
studies, differences in definitions of prescriber and patient
characteristics (which were often not provided, i.e.,
whether patients had valvular and non-valvular AF), and
changes in warfarin use over time. We attempted to limit
the influence of the latter by restricting our analysis to
studies published during or after 1996. Furthermore, as
with any systematic review and meta-analysis, we can not
rule out the possibility of publication bias (bias due to
incomplete data). While Egger’s weighted regression sta-
tistic p-values for all characteristics meta-analyzed sug-
gested a lower likelihood of publication bias, many
characteristics could not be adequately evaluated because
of limited data points or their inappropriateness for pool-
ing. As this was a systematic review and meta-analysis of
observational studies, it is also possible that publication
bias may occur as a result of authors failing to report non-
significant finds from their multivariate analyses. How-
ever, we are less concerned about this type of negative
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reporting bias since a large majority of all identified stu-
dies reported at least one nonsignificant finding.
Conclusion
Implications for Practice
Warfarin use has increased somewhat over time. Evidence
suggests that the decision to prescribe warfarin for stroke
prevention in patients with atrial fibrillation is based upon
multiple prescriber and patient characteristics. These find-
ings can be used by family practice prescribers and other
healthcare decision-makers to target interventions or
methods to improve utilization of warfarin when it is indi-
cated for stroke prevention.
Implications for Research
Future studies evaluating predictors of warfarin prescrib-
ing in AF patients should focus on prescriber and/or
patient characteristics that have never been previously or
are infrequently evaluated. In addition, targeted interven-
tions addressing modifiable prescriber and/or patient char-
acteristics identified in this review should undergo
evaluation to test their effectiveness at increasing proper
warfarin prescription.
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